ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) - Trial NCT06042855
Access comprehensive clinical trial information for NCT06042855 through Pure Global AI's free database. This Phase 3 trial is sponsored by Susanna Naggie, MD and is currently Recruiting. The study focuses on Covid19. Target enrollment is 15000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Susanna Naggie, MD
Duke University
Timeline & Enrollment
Phase 3
Sep 05, 2023
Mar 01, 2024
Primary Outcome
Time to sustained recovery in Days,Number of Participants With Hospitalization or Death
Summary
The purpose of this study is to evaluate the effectiveness of repurposed medications (study
 drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19.
 Participants will receive either study drug or placebo. Participants will self-report any new
 or worsening symptoms or medical events experienced while taking study drug or placebo. This
 study is intended to be all remote with no in person visits, unless the study team feels it
 is in the best interest of a participant to be seen in person.
 
 Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the
 activation of any new drug arms. Each study arm will also have its own clinicaltrials.gov
 entry and will include Pro00107921 in the Unique Protocol ID.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06042855
Non-Device Trial